Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 1032638, 10 pages
https://doi.org/10.1155/2018/1032638
Research Article

Biological Effects and Biodistribution of Bufotenine on Mice

1Laboratory of Biochemistry and Biophysics, Butantan Institute, SP, Brazil
2Special Laboratory for Applied Toxinology, Butantan Institute, SP, Brazil
3Laboratory of Cell Biology, Butantan Institute, SP, Brazil

Correspondence should be addressed to Juliana Mozer Sciani; rb.vog.natnatub@inaicsmj

Received 20 February 2018; Accepted 2 May 2018; Published 31 May 2018

Academic Editor: Jane Hanrahan

Copyright © 2018 Hugo Vigerelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Sciani, C. B. Angeli, M. M. Antoniazzi, C. Jared, and D. C. Pimenta, “Differences and similarities among parotoid macrogland secretions in south american toads: a preliminary biochemical delineation,” The Scientific World Journal, vol. 2013, Article ID 937407, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. T. A. Smith, “Tryptamine and related compounds in plants,” Phytochemistry, vol. 16, no. 2, pp. 171–175, 1977. View at Publisher · View at Google Scholar · View at Scopus
  3. V. L. Stromberg, “The isolation of bufotenine from piptadenia peregrina,” Journal of the American Chemical Society, vol. 76, no. 6, p. 1707, 1954. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Handovsky, “Ein Alkaloid im Gifte von Bufo vulgaris - Ausgeführt mit Unterstützung der Fürst-Liechtenstein-Spende in Wien und der Gesellschaft zur Förderung deutscher Wissenschaft, Kunst und Literatur in Böhmen,” Archiv für Experimentelle Pathologie und Pharmakologie, vol. 86, no. 1-2, pp. 138–158, 1920. View at Publisher · View at Google Scholar · View at Scopus
  5. W. S. Chilton, J. Bigwood, and R. E. Jensen, “Psilocin, bufotenine and serotonin: historical and biosynthetic observations,” Journal of Psychoactive Drugs, vol. 11, no. 1-2, pp. 61–69, 1979. View at Publisher · View at Google Scholar · View at Scopus
  6. D. J. McKenna and G. H. N. Towers, “Biochemistry and pharmacology of tryptamines and beta-carbolines a minireview,” Journal of Psychoactive Drugs, vol. 16, no. 4, pp. 347–358, 1984. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Davis and A. T. Weil, “Identity of a new world psychoactive toad,” Ancient Mesoamerica, vol. 3, no. 1, pp. 51–59, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Jacob III and A. T. Shulgin, “Structure-activity relationships of the classic hallucinogens and their analogs,” NIDA Research Monograph, no. 146, pp. 74–91, 1994. View at Google Scholar · View at Scopus
  9. T. Lyttle, D. Goldstein, and J. Gartz, “Bufo toads and bufotenine: fact and fiction surrounding an alleged psychedelic,” Journal of Psychoactive Drugs, vol. 28, no. 3, pp. 267–290, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. M. C. McBride, “Bufotenine: toward an understanding of possible psychoactive mechanisms,” Journal of Psychoactive Drugs, vol. 32, no. 3, pp. 321–331, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Ott, “Pharmañopo—Psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine,” Journal of Psychoactive Drugs, vol. 33, no. 3, pp. 273–281, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Vigerelli, J. M. Sciani, C. Jared et al., “Bufotenine is able to block rabies virus infection in BHK-21 cells,” Journal of Venomous Animals and Toxins including Tropical Diseases, vol. 20, no. 1, Article ID 45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Finke and K.-K. Conzelmann, “Replication strategies of rabies virus,” Virus Research, vol. 111, no. 2, pp. 120–131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. R. d. S. C. Neto, H. Vigerelli, C. Jared et al., “Synergic effects between ocellatin-F1 and bufotenine on the inhibition of BHK-21 cellular infection by the rabies virus,” Journal of Venomous Animals and Toxins including Tropical Diseases, vol. 21, no. 1, Article ID 50, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. D. L. Knobel, S. Cleaveland, P. G. Coleman et al., “Re-evaluating the burden of rabies in Africa and Asia,” Bulletin of the World Health Organization, vol. 83, no. 5, pp. 360–368, 2005. View at Google Scholar · View at Scopus
  16. W. H. Wunner, D. J. Briggs, and P. Sinnis, “Rabies in the 21st Century,” PLOS Neglected Tropical Diseases, vol. 4, no. 3, p. e591, 2010. View at Publisher · View at Google Scholar
  17. A. C. Jackson, “Current and future approaches to the therapy of human rabies,” Antiviral Research, vol. 99, no. 1, pp. 61–67, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. R. E. Willoughby Jr., K. S. Tieves, G. M. Hoffman et al., “Survival after treatment of rabies with induction of coma,” The New England Journal of Medicine, vol. 352, no. 24, pp. 2508–2514, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. F. A. Zeiler and A. C. Jackson, “Critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned,” Canadian Journal of Neurological Sciences, vol. 43, no. 1, pp. 44–51, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. F.-X. Meslin, M. M. Kaplan, and H. Koprowski, World Health O: Laboratory Techniques in Rabies, 1996.
  21. R. N. Walsh and R. A. Cummins, “The open-field test: a critical review,” Psychological Bulletin, vol. 83, no. 3, pp. 482–504, 1976. View at Publisher · View at Google Scholar · View at Scopus
  22. J. N. Crawley, “Exploratory behavior models of anxiety in mice,” Neuroscience & Biobehavioral Reviews, vol. 9, no. 1, pp. 37–44, 1985. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Prut and C. Belzung, “The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review,” European Journal of Pharmacology, vol. 463, no. 1–3, pp. 3–33, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. L. C. U. Junqueira, “Histology revisited: technical improvement promoted by the use of hydrophilic resin embedding,” Ciênc cult (Säo Paulo), vol. 47, pp. 92–95, 1995. View at Google Scholar
  25. S. McClean, R. C. Robinson, C. Shaw, and W. F. Smyth, “Characterisation and determination of indole alkaloids in frog-skin secretions by electrospray ionisation ion trap mass spectrometry,” Rapid Communications in Mass Spectrometry, vol. 16, no. 5, pp. 346–354, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Osmond, “A review of the clinical effects of psychotomimetic agents,” Annals of the New York Academy of Sciences, vol. 66, no. 3, pp. 418–434, 1957. View at Publisher · View at Google Scholar · View at Scopus
  27. D. E. Nichols, “Hallucinogens,” Pharmacology & Therapeutics, vol. 101, no. 2, pp. 131–181, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. J. González-Maeso and S. C. Sealfon, “Agonist-trafficking and hallucinogens,” Current Medicinal Chemistry, vol. 16, no. 8, pp. 1017–1027, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Bielenica, E. Kȩdzierska, M. Koliński et al., “5-HT2 receptor affinity, docking studies and pharmacological evaluation of a series of 1,3-disubstituted thiourea derivatives,” European Journal of Medicinal Chemistry, vol. 116, pp. 173–186, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Fiorino, E. Magli, E. Kędzierska et al., “New 5-HT1A, 5HT2A and 5HT2C receptor ligands containing a picolinic nucleus: synthesis, in vitro and in vivo pharmacological evaluation,” Bioorganic & Medicinal Chemistry, vol. 25, no. 20, pp. 5820–5837, 2017. View at Publisher · View at Google Scholar · View at Scopus
  31. S. J. Peroutka, “The molecular pharmacology of 5-hydroxytryptamine receptor subtypes,” in Serotonin Receptor Subtypes: Basic and Clinical Aspects, pp. 65–80, 1991. View at Publisher · View at Google Scholar
  32. M. S. Choudhary, S. Craigo, and B. L. Roth, “A single point mutation (Phe340→Leu340) of a conserved phenylalanine abolishes 4-[125I]lodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors,” Molecular Pharmacology, vol. 43, no. 5, pp. 755–761, 1993. View at Google Scholar · View at Scopus
  33. N. Almaula, B. J. Ebersole, J. A. Ballesteros, H. Weinstein, and S. C. Sealfon, “Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine(2A) and 5- hydroxytryptamine(2C) receptors: direct and indirect effects on ligand affinity mediated by the same locus,” Molecular Pharmacology, vol. 50, no. 1, pp. 34–42, 1996. View at Google Scholar · View at Scopus
  34. N. Almaula, B. J. Ebersole, D. Zhang, H. Weinstein, and S. C. Sealfon, “Mapping the Binding Site Pocket of the Serotonin 5-Hydroxytryptamine,” The Journal of Biological Chemistry, vol. 271, no. 25, pp. 14672–14675, 1996. View at Publisher · View at Google Scholar
  35. B. L. Roth, M. S. Choudhary, N. Khan, and A. Z. Uluer, “High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine(2A) receptors: evidence in favor of a modified ternary complex model,” The Journal of Pharmacology and Experimental Therapeutics, vol. 280, no. 2, pp. 576–583, 1997. View at Google Scholar · View at Scopus
  36. E. Zifa and G. Fillion, “5-Hydroxytryptamine receptors,” Pharmacological Reviews, vol. 44, no. 3, pp. 401–458, 1992. View at Google Scholar · View at Scopus
  37. A. L. Halberstadt, I. Van Der Heijden, M. A. Ruderman et al., “5-HT 2A and 5-HT 2C receptors exert opposing effects on locomotor activity in mice,” Neuropsychopharmacology, vol. 34, no. 8, pp. 1958–1967, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. C. S. Hall, “Emotional behavior in the rat. I. Defecation and urination as measures of individual differences in emotionality,” Journal of Comparative Psychology, vol. 18, no. 3, pp. 385–403, 1934. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Bindra and W. R. Thompson, “An evaluation of defecation and urination as measures of fearfulness,” Journal of Comparative and Physiological Psychology, vol. 46, no. 1, pp. 43–45, 1953. View at Publisher · View at Google Scholar · View at Scopus
  40. R. G. Lister, “Ethologically-based animal models of anxiety disorders,” Pharmacology & Therapeutics, vol. 46, no. 3, pp. 321–340, 1990. View at Publisher · View at Google Scholar · View at Scopus
  41. R. A. Glennon, P. K. Gessner, D. D. Godse, and B. J. Kline, “Bufotenine esters,” Journal of Medicinal Chemistry, vol. 22, no. 11, pp. 1414–1416, 1979. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Lyttle, “Misuse and legend in the "toad licking" phenomenon,” Substance Use & Misuse, vol. 28, no. 6, pp. 521–538, 1993. View at Publisher · View at Google Scholar · View at Scopus
  43. G. P. Migliaccio, T.-L. N. Shieh, S. R. Byrn, B. A. Hathaway, and D. E. Nichols, “Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy,” Journal of Medicinal Chemistry, vol. 24, no. 2, pp. 206–209, 1981. View at Publisher · View at Google Scholar · View at Scopus
  44. W. H. Vogel and B. D. Evans, “Structure-activity-relationships of certain hallucinogenic substances based on brain levels,” Life Sciences, vol. 20, no. 10, pp. 1629–1635, 1977. View at Publisher · View at Google Scholar · View at Scopus
  45. R. W. Fuller, H. D. Snoddy, and K. W. Perry, “Tissue distribution, metabolism and effects of bufotenine administered to rats,” Neuropharmacology, vol. 34, no. 7, pp. 799–804, 1995. View at Publisher · View at Google Scholar · View at Scopus
  46. R. E. Kantor, S. D. Dudlettes, and A. T. Shulgin, “5-Methoxy-α-methyltryptamine (α-O-dimethylserotonin), a hallucinogenic homolog of serotonin,” Biological Psychiatry, vol. 15, no. 2, pp. 349–352, 1980. View at Google Scholar · View at Scopus
  47. J. W. Lohr, G. R. Willsky, and M. A. Acara, “Renal drug metabolism,” Pharmacological Reviews, vol. 50, no. 1, pp. 107–141, 1998. View at Google Scholar · View at Scopus
  48. C. M. Torres and D. B. Repke, Anadenanthera: Visionary Plant of Ancient South America, Psychology Press, 2006.
  49. D. Obreshkova, I. Kandilarov, V. T. Angelova, Y. Iliev, P. Atanasov, and P. S. Fotev, “Pharmaco-toxicological aspects and analysis of phenylalkylamine and indolylalkylamine hallucinogens,” Pharmacia, vol. 64, pp. 32–47, 2017. View at Google Scholar